1. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely, & Jones, 1817.
2. Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48(8): 938-942.
3. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43(11):2227-2229.
4. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003; 60(11):1756-1761.
5. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995; 45(4):669-671.
6. Aarsland D, Larsen JP, Karlsen K, et al. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14(10):866-874.
Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 2002; 59(11):1724-1728.
Aarsland D, Tandberg E, Larsen JP, et al. Frequency of dementia in Parkinson disease. Arch Neurol 1996; 53(6):538-542.
Fernandez HH, Lapane KL. Predictors of mortality among nursing home residents with a diagnosis of Parkinson's disease. Med Sci Monit 2002; 8(4):CR241-246. Hughes TA, Ross HF, Mindham RH, et al. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004; 110(2):118-123. de Lau LM, Schipper CM, Hofman A, et al. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol 2005; 62(8):1265-1269. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association, 1994. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123 (Pt 4):733-745.
Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996; 53(12):1265-1268.
Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70(6):734-738. Chou KL, Messing S, Oakes D, et al. Drug-induced psychosis in parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharma-col 2005; 28(5):215-219.
Factor SA, Molho ES, Podskalny GD, et al. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995; 65:115-138.
Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol 1993; 60:703-706.
Marsh L, Williams JR, Rocco M, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004; 63(2):293-300.
Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991; 39(7):708-716.
Fernandez HH, Friedman JH. The role of atypical antipsychotics in the treatment of movement disorders. CNS drugs 1999; 11(6):467-483.
Fischer P, Danielczyk W, Simanyi M, et al. Dopaminergic psychosis in advanced Parkinson's disease. Adv Neurol 1990; 53:391-397.
Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982; 139(4):494-497.
Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64(4):533-535.
Tousi B, Frankel M. Olfactory and visual hallucinations in Parkinson's disease. Parkin-sonism Relat Disord 2004; 10(4):253-254.
Cahn-Weiner DA, Grace J, Ott BR, et al. Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's disease. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15(2):79-87.
Cummings JL. The Neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology 1997; 48(5 suppl 6):S10-S16.
Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48(suppl:9-15. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry 1989; 155(suppl. 7):59-67. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa, 1984.
Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville, Md.: Alcohol, Drug Abuse and Mental Health Administration, 1976.
35. Friedberg G, Zoldan J, Weizman A, et al. Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol 1998; 21(5):280-284.
36. Klawans HL, Goetz C, Nausieda PA, et al. Levodopa-induced dopamine receptor hypersensitivity. Trans Am Neurol Assoc 1977; 102:80-83.
37. Rondot P, de Recondo J, Coignet A, et al. Mental disorders in Parkinson's disease after treatment with L-DOPA. Adv Neurol 1984; 40:259-269.
38. Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings). J Neural Transm 1975; 37(2):175-182.
39. Nausieda PA, Tanner CM, Klawans HL. Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. Adv Neurol 1983; 37:23-32.
40. Melamed E, Zoldan J, Friedberg G, et al. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Adv Neurol 1996; 69:545-550.
41. Diederich NJ, Goetz CG, Raman R, et al. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol 1998; 21(5):289-295.
42. Matsui H, Udaka F, Tamura A, et al. The relation between visual hallucinations and visual evoked potential in Parkinson disease. Clin Neuropharmacol 2005; 28(2):79-82.
43. Diederich NJ, Alesch F, Goetz CG. Visual hallucinations induced by deep brain stimulation in Parkinson's disease. Clin Neuropharmacol 2000; 23(5):287-289.
44. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 2004; 63(8):1409-1416.
45. Aarsland D, Larsen JP, Cummins JL, et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999; 56(5):595-601.
46. Arnulf I, Bonnet AM, Damier P, et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 2000; 55(2):281-288.
47. Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenom-enological survey. J Neurol Neurosurg Psychiatry 2001; 70(6):727-733.
48. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 1993; 34(5):710-714.
49. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA 2000; 284(15):1931-1938.
50. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342(20):1484-1491.
51. Klein C, Kompf D, Pulkowski U, et al. A study of visual hallucinations in patients with Parkinson's disease. J Neurol 1997; 244(6):371-377.
52. Merims D, Shabtai H, Korczyn AD, et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm 2004; 111(10-11):1447-1453.
53. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15(2):201-211.
54. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294(15):1934-1943.
55. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991; 324(11):746-754.
56. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340(10):757-763.
57. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75(5):689-695.
58. Wolters EC, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40(5):832-834.
59. French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999, 353(9169):2041-2042.
61. Klein C, Gordon J, Pollak L, et al. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuropharmacol 2003; 26(1):8-11.
62. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59(suppl 3):3-7.
64. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60(2):107-115.
65. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 1999; 52(4):782-785.
66. Ellis T, Cudkowicz ME, Sexton PM, et al. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000; 12(3):364-369.
67. Workman RH, Jr., Orengo CA, Bakey AA, et al. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neu-rosci 1997; 9(4):594-597.
68. Meco G, Alessandria A, Bonifati V, et al. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 1994; 343(8909):1370-1371.
69. Allen RL, Walker Z, D'Ath PJ, et al. Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet 1995; 346(8968):185.
70. McKeith IG, Ballard CG, Harrison RW. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 1995; 346(8976):699.
71. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease. Lancet 1994; 344(8923):681.
72. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56(12):556-559.
73. Meco G, Alessandri A, Giustini P, et al. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov Disord 1997; 12(4):610-612.
74. Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000; 15(2):301-304.
75. Mohr E, Mendis T, Hildebrand K, et al. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000; 15(6): 1230-1237.
76. Moore NA, Tye NC, Axton MS, et al. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992; 262(2):545-551.
77. Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997; 58(suppl 10):7-12.
78. Wolters EC, Jansen EN, Tuynman-Qua HG, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47(4):1085-1087.
79. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 2003; 26(9):643-659.
80. Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55(6):789-794.
81. Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002; 17(5):1031-1035.
82. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002; 52(5):438-445.
83. Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson's disease. Mov Disord 2002; 17(suppl 4):S120-S127.
84. Sailer CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993; 112(2-3):285-292.
85. Reddy S, Factor SA, Molho ES, et al. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002; 17(4): 676-681.
86. Fernandez HH, Trieschmann ME, Burke MA, et al. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003; 18(5):510-514.
87. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27(4):153-156.
88. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20(8):958-963.
89. Rabey JM, Prokhorov T, Miniovich A, et al. The effect of quetiapine in Parkinson's disease (PD) psychotic patients: A double-blind labeled study of three months duration. Mov Disord 2005; 20(suppl 10):S46.
90. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003; 64(suppl 19):6-12.
91. Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005; 66(suppl 6):5-10.
92. Gomez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol 2005; 28(3):111-114.
93. Oechsner M, Korchounov A. Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease? Hum Psychopharmacol 2005; 20(3):203-205.
94. Weiden PJ, Iqbal N, Mendelowitz AJ, et al. Best clinical practice with ziprasidone: update after one year of experience. J Psychiatr Pract 2002; 8(2):81-97.
95. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004; 27(1):4-5.
96. Friedman JH, Berman RM, Carson W, et al. Low dose aripiprazole for the treatment of drug induced psychosis in Parkinson's disease patients. Mov Disord 2005; 20(suppl 10):S92.
97. White A, Corn TH, Feetham C, et al. Ondansetron in treatment of schizophrenia. Lancet 1991; 337(8750):1173.
98. Zoldan J, Friedberg G, Goldberg-Stern H, et al. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993; 341(8844):562-563.
99. Zoldan J, Friedberg G, Livneh M, et al. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45(7):1305-1308.
100. Eichhorn TE, Brunt E, Oertel WH. Ondansetron treatment of L-dopa-induced psychosis. Neurology 1996; 47(6):1608-1609.
101. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50(1):136-145.
102. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54(12): 2269-2276.
103. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 61(3):324-325.
104. Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002; 23(1):41-43.
105. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002; 25(2):107-110.
106. Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. J Geriatr Psychiatry Neurol 2003; 16(3):184-188.
107. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76(7):934-939.
Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002; 18(5):258-264.
Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16(6):1171-1174.
Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351(24):2509-2518.
Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galan-tamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003; 18(10):937-941. Ozer F, Meral H, Aydin B, et al. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J Ect 2005; 21(2):125-127. Hurwitz TA, Calne DB, Waterman K. Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy. Can J Neurol Sci 1988; 15(1):32-34. Factor SA, Molho ES, Brown DL. Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1995; 7(3):304-307.
Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord 2004; 19(7):831-833. Fernandez HH, Trieschmann ME, Okun MS. Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease. Mov Disord 2005; 20(1):104-105. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997; 244(1):2-8. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004; 61(12):1906-1911.
McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47(5):1113-1124.
Cummings JL. Third International Workshop on Dementia with Lewy Bodies and Parkinson's disease Dementia. Newcastle upon Tyne, United Kingdom: MedReviews, LLC, 2003:31-34.
Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004; 17(3):137-145. McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 1999; 53(5):902-905.
Girotti F, Soliveri P, Carella F, et al. Dementia and cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51(12):1498-1502.
Mayeux R, Stern Y, Rosenstein R, et al. An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol 1988; 45(3):260-262.
Friedman A, Barcikowska M. Dementia in Parkinson's disease. Dementia 1994; 5(1): 12-16.
Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60(3):387-392. Tison F, Dartigues JF, Auriacombe S, et al. Dementia in Parkinson's disease: a population-based study in ambulatory and institutionalized individuals. Neurology 1995; 45(4): 705-708.
Hobson P, Meara J. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age Ageing 1999; 28(1):39-43.
Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 2004; 19(9):1043-1049. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005; 20(10):1255-1263.
Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000; 54(8):1596-1602. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001; 56(6):730-736.
133. Marder K, Tang MX, Cote L, et al. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995; 52(7):695-701.
134. Levy G, Schupf N, Tang MX, et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002; 51(6):722-729.
135. Fernandez HH, Crucian GP, Seignourel P, et al. Laterality, location, type and severity of motor dysfunction may predict cognitive decline in Parkinson's disease. Mov Disord 2005; 20:1243.
136. Levy G, Tang MX, Cote LJ, et al. Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study. Mov Disord 2002; 17(2):250-257.
137. Harhangi BS, de Rijk MC, van Duijn CM, et al. APOE and the risk of PD with or without dementia in a population-based study. Neurology 2000; 54(6):1272-1276.
138. Parsian A, Racette B, Goldsmith LJ, et al. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 2002;79(3):458-461.
139. Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28(4):547-555.
140. Chou KL, Hurtig HI, Stern MB, et al. Diagnostic accuracy of [(99m)Tc]TRODAT-1 SPECT imaging in early Parkinson's disease. Parkinsonism Relat Disord 2004; 10(6):375-379.
141. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38(4):589-598.
142. Rinne JO, Rummukainen J, Paljarvi L, et al. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989; 26(1):47-50.
143. Growdon JH, Kieburtz K, McDermott MP, et al. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group. Neurology 1998; 50(5):1327-1331.
144. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985; 48(5):413-421.
145. Whitehouse PJ, Hedreen JC, White CL 3rd, et al. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983; 13(3):243-248.
146. Mattila PM, Roytta M, Lonnberg P, et al. Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol (Berl) 2001; 102(2):160-166.
147. Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993; 7(2):69-79.
148. Ruberg M, Ploska A, Javoy-Agid F, et al. Muscarinic binding and choline acetyltrans-ferase activity in Parkinsonian subjects with reference to dementia. Brain Res 1982; 232(1):129-139.
149. Cash R, Dennis T, L'Heureux R, et al. Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology 1987; 37(1):42-46.
150. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991; 50(6):743-755.
151. Brown DF, Dababo MA, Bigio EH, et al. Neuropathologic evidence that the Lewy body variant of Alzheimer disease represents coexistence of Alzheimer disease and idiopathic Parkinson disease. J Neuropathol Exp Neurol 1998; 57(1):39-46.
152. Hughes AJ, Daniel SE, Blankson S, et al. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50(2):140-148.
153. Jellinger KA. Morphological substrates of dementia in parkinsonism. A critical update. J Neural Transm Suppl 1997; 51:57-82.
154. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54(10):1916-1921.
155. Ince P, Irving D, MacArthur F, et al. Quantitative neuropathological study of Alzheimertype pathology in the hippocampus: comparison of senile dementia of Alzheimer type, senile dementia of Lewy body type, Parkinson's disease and non-demented elderly control patients. J Neurol Sci 1991; 106(2):142-152.
156. Apaydin H, Ahlskog JE, Parisi JE, et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002; 59(1):102-112.
157. Physicians Desk Reference. 56th ed. Montvale, NJ: Medical Economics Company, Inc., 2002.
158. Whitehouse PJ. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease. Adv Neurol 1987; 45:393-397.
159. Grace J, Daniel S, Stevens T, et al. Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001; 13(2):199-205.
160. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356(9247):2031-2036.
161. Aarsland D, Bronnick K, Karlsen K. Donepezil for dementia with Lewy bodies: a case study. Int J Geriatr Psychiatry 1999; 14(1):69-72.
162. Kaufer DI, Catt KE, Lopez OL, et al. Dementia with Lewy bodies: response of deliriumlike features to donepezil. Neurology 1998; 51(5):1512.
163. Lanctot KL, Herrmann N. Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int J Geriatr Psychiatry 2000; 15(4):338-345.
164. Giladi N, Shabtai H, Gurevich T, et al. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand 2003; 108(5):368-373.
165. Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003; 18(11):988-993.
166. Werber EA, Rabey JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 2001; 108(11):1319-1325.
167. Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72(6):708-712.
168. Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004; 19(1):1-8.
169. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study. Mov Disord 2006; 21(4):456-461.
170. Bedard MA, el Massioui F, Malapani C, et al. Attentional deficits in Parkinson's disease: partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist. Clin Neuropharmacol 1998; 21(2):108-117.
171. Marder K, Tang MX, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998; 50(4):1141-1143.
172. Fernandez HH, Lapane KL. Estrogen use among nursing home residents with a diagnosis of Parkinson's disease. Mov Disord 2000; 15(6):1119-1124.
Was this article helpful?
The comprehensive new ebook All About Alzheimers puts everything into perspective. Youll gain insight and awareness into the disease. Learn how to maintain the patients emotional health. Discover tactics you can use to deal with constant life changes. Find out how counselors can help, and when they should intervene. Learn safety precautions that can protect you, your family and your loved one. All About Alzheimers will truly empower you.